Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading China-based Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of a state-of-the-art Active Pharmaceutical Ingredient (API) pilot plant and R&D laboratory in Sandwich, UK. These facilities, previously under the ownership of US pharmaceutical giant Pfizer, mark Asymchem’s inaugural foray into Europe’s R&D and manufacturing sector, signifying the company’s ambition to bolster its global CDMO capabilities.
Established in 1954, the Sandwich site is renowned for its world-class rapid design, high-throughput screening of drug synthesis routes, and boasts mature process and analytical development capabilities, as well as robust production and operational management expertise. Asymchem is set to assume operations of the R&D center and production workshop in June 2024, at which time it will be poised to leverage the professional technology and management teams, formerly of Pfizer UK, to undertake CDMO projects from clients globally.- Flcube.com
